Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial.

ABSTRACT:

Background

Arginine vasopressin 1B receptor (V_1B) antagonists may have utility for the treatment of major depressive disorder (MDD).

Methods

The V_1B antagonist ABT-436 (N = 31) or matching placebo (N = 20) was administered to MDD subjects for 7 days. The main study objectives were to assess the safety and hypothalamic-pituitary-adrenal axis (HPA) effects of ABT-436 in MDD subjects. MDD symptoms were assessed using the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the subject-rated Mood and Anxiety Symptom Questionnaire (MASQ).

Results

The most prevalent safety finding associated with ABT-436 800 mg QD was increased mild-moderate diarrhea (68% v 5%, p < 0.001). Increased nausea (26% v 5%, p < 0.10), decreased

SUBMITTER: Katz DA 

PROVIDER: S-EPMC5346517 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature